Genital Herpes Treatment Market Snapshot
Future Market Insights (FMI) in its latest market analysis forecasts that genital herpes treatment sales will accelerate at 1.5x in next ten years reaching the market valuation of US$ 2881.8 Mn by the end of 2031.
North America genital herpes treatment market will hold around 34.3% of global market share by 2021 owing to rising prevalence of genital herpes in U.S. and increasing healthcare spending in the region, as per FMI’s finding.
Growth predictions remain positive for Europe due to rising awareness regarding sexually transmissible infections and presence of leading market players in the U.K. and Germany. Spurred by this, the Europe genital herpes treatment market is projected to grow at about 3.4% CAGR during the forecast period.
Key Points Covered in Genital Herpes Treatment Market Study
- Market estimates and forecast 2021 – 2031
- Key drivers and restrains impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competitive Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact On Genital Herpes Treatment Market and How to Navigate
- Recommendation on Key Winning Strategies
2016 – 2020 Genital Herpes Treatment Market Outlook In Comparison to 2021 – 2031 Forecasts
Genital herpes cases are on the rise in western hemisphere especially in U.S., U.K. and Germany. The Center of Disease Control and Prevention states that one out of every six people in U.S. between the ages of 14 to 49 years is affected with genital herpes.
Increase in demand for genital herpes treatment will create prospects for expansion of the market. FMI reports that the genital herpes treatment market showcased a modest growth of 4% CAGR in past five years.
Rising cases of genital herpes in countries in Asia such as China and India will rev up growth opportunities for the market. The growth trend will continue in response to increasing healthcare spending registered in emerging economies.
Vaccine development for genital herpes is on the cards as pharmaceutical market leaders are focusing on new drug development and are also collaborating with research institutes for clinical trials and faster product development.
For instance, Sanofi Pasteur in collaboration with National Institute of Allergy and Infectious Diseases is currently developing a herpes vaccine called HSV529 (HSV15). The vaccine is classified as a replication-defective virus which means the virus possesses all the HSV virus components except two proteins important UL5 and UL29, involved in viral DNA replication.
In March 2021, GlaxoSmithKline plc began its phase 1 human clinical trials for its experimental HSV-2 vaccine to study the reactogenicity, safety, and immunogenicity of four different dose levels of the vaccine in healthy participants aged 18-40 years.
Rapid advancement in the field of virology and increasing investment towards modern medicine and therapeutic treatment development will boost the genital herpes treatment market growth globally throughout upcoming decade.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Famciclovir to emerge as another lucrative drug type after a long rule by Acyclovir
The genital herpes treatment includes the use of drug types like Acyclovir that can treat herpes virus infections, including shingles. This medication does not cure herpes, but may prevent herpes sores or blisters.
It is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Zovirax is the main brand available in the market for genital herpes. It can also treat chickenpox.
The other one is Valacyclovir which is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster).
In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. It is an influenza antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. Famciclovir is an antiviral drug. However, it is not a cure for these infections.
The viruses that cause these infections continue to live in the body even between outbreaks. Famvir is typically used as a one-time treatment that stops the spread or prevents the symptoms from becoming a hassle.
It treats shingles caused by herpes zoster. It also treats outbreaks of herpes simplex that cause cold sores around the mouth, sores around the anus, and genital herpes.
Among these drug types prevalent in the genital herpes treatment, Acyclovir segment dominated the global genital herpes treatment market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period.
However, Famciclovir is a drug type that is expected to gain popularity in the forecast period, and grow at a high CAGR of 5.0% during the forecast period.
Increasing demand for genital herpes treatment drugs by homosexuals to be observed in the coming years
The detailed analysis of genital herpes treatment market has helped the researchers to get crucial insights. It includes results like more prevalence of HSV-2 in homosexuals. Chances of genital herpes are more in the male same-sex partnership compared to female same-sex partnership. Homosexual men are known to be at high risk for herpes simplex virus (HSV), which can be transmitted by direct intimate contact with a person who is shedding virus, and not only through ano-genital sex.
Herpes virus type 2 (HSV2) is generally considered as a useful marker for sexual behavior in a population 50% of the homosexual population in Latin America has the risk of sexually transmitted diseases such as HSV-2 genital herpes and HIV, which would increase the demand for genital herpes treatment and drive the market.
A new trend depicts increasing clinical trial of vaccines for genital herpes
Companies are increasing the clinical trials for genital herpes vaccine for advance prevention & treatment of genital herpes. Geneva is developing vaccines for genital herpes and doing clinical trial of GEN-003. It is potentially the first-ever therapeutic vaccine for a chronic infection and first advancement in the treatment of genital herpes in more than 20 years. GEN-003 is a Phase 3-ready investigational immunotherapy for the treatment of genital herpes infections. These new developments will increase the growth of the genital herpes treatment market especially in Western Europe.
Global Genital Herpes Treatment Market: Top Companies
Some of the leading companies mentioned in the research report are Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Sun Pharmaceuticals Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, ltd., Novartis AG, Valeant Pharmaceuticals International Inc. etc.
This list is indicative - full details about prominent genital herpes treatment manufacturers is available upon request
Genital herpes Treatment Market – Report Scope
2021 – 2031
Historical Data Available for
2017 – 2027
US$ Mn for Value & Units for Volume
Key Regions Covered
North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa
Key Countries Covered
U.S., Canada, Brazil, Mexico, Argentina, Rest of Latin America, EU-5, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Denmark, Finland, Iceland, Norway, Sweden), Rest of Western Europe, Poland, Russia, Rest of Eastern Europe, China, India, Japan, GCC Countries, South Africa, Israel, Turkey, Iran, Rest of Middle East & Africa, Australia, New Zealand, South Korea, the Philippines, Malaysia, and Thailand
Key Segments Covered
Drug type, Distribution Channel, Route of Administration, Indication and Region
Key Companies Profiled
Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis
Customization & Pricing
Available upon Request
Key Questions Answered in the Report
How much is the genital herpes treatment market worth?
Driven by increasing prevalence of genital herpes in younger population across the globe, the genital herpes treatment market is forecast to grow at 4.76% from 2021, reaching the valuation of US$ 1947.2 Mn in 2021.
At what rate did the genital herpes treatment market expand in the last five years?
Between 2016 and 2020, the genital herpes treatment market grew at a 4.0% CAGR.
What will be the demand outlook/ sales forecast of genital herpes treatment?
The global genital herpes treatment sale is forecast to exceed the valuation of US$ 2881.8 Mn by the end of 2031.
Which countries are key producers of genital herpes treatment?
Leading countries driving the production of the genital herpes treatment are U.S., China, and India.
What is the North America genital herpes treatment market outlook?
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America will engulf around 34.2% of global market share by 2031.
Who are the leading five companies in genital herpes treatment market?
Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd and Abbott Laboratories are the top five companies operating in the market.
What is the cumulative share of top companies in genital herpes treatment market?
Top five market players account for around 54.5% of the global genital herpes treatment market share.
At what rate will genital herpes treatment sales increase in Europe?
Genital herpes treatment sales will increase at 3.4% CAGR in Europe, backed by rising demand in the U.K., Germany, and other countries.
Which are the top five countries driving genital herpes treatment market demand?
Leading countries driving demand in the genital herpes treatment market are U.S., China, India Germany, and U.K.
What are the key statistics for genital herpes treatment market in China and Japan?
Japan and China held 7.1% and 3.6% share, respectively in the overall genital herpes treatment market in 2021.
Key Segments Covered in Genital herpes treatment Market Study
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Route of Administration:
Key Regions/Countries Covered:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Ex. Japan (APEJ)
- Middle East & Africa